Adamson feels that drug developers are unreasonably concerned about rare events. The reality is children tolerate phase I therapy new agents being tested to find the best dosage and possible side-effects as well as or better than adults, ... Once the initial studies are done that is, phase I trials in adults study should begin in children.
